Handelsbanken Fonder AB Acquires 2,500 Shares of Prothena Co. plc (NASDAQ:PRTA)

Handelsbanken Fonder AB increased its position in shares of Prothena Co. plc (NASDAQ:PRTA) by 4.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 61,400 shares of the biotechnology company’s stock after buying an additional 2,500 shares during the period. Handelsbanken Fonder AB owned 0.11% of Prothena worth $2,231,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of PRTA. Raymond James & Associates boosted its holdings in shares of Prothena by 98.4% during the 3rd quarter. Raymond James & Associates now owns 8,167 shares of the biotechnology company’s stock worth $394,000 after buying an additional 4,050 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Prothena by 12.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,464 shares of the biotechnology company’s stock worth $360,000 after buying an additional 797 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Prothena by 14.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,652 shares of the biotechnology company’s stock worth $1,238,000 after buying an additional 3,222 shares during the period. TD Asset Management Inc boosted its holdings in shares of Prothena by 93.1% during the 3rd quarter. TD Asset Management Inc now owns 172,682 shares of the biotechnology company’s stock worth $8,332,000 after buying an additional 83,269 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Prothena by 58.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,096 shares of the biotechnology company’s stock worth $149,000 after buying an additional 1,140 shares during the period. 97.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on PRTA. JMP Securities increased their price target on shares of Prothena from $81.00 to $85.00 and gave the company a “market outperform” rating in a report on Friday, February 16th. Bank of America reissued a “neutral” rating and issued a $38.00 price target (down from $68.00) on shares of Prothena in a report on Tuesday, January 30th. StockNews.com downgraded shares of Prothena from a “hold” rating to a “sell” rating in a report on Monday, February 19th. Royal Bank of Canada reduced their price target on shares of Prothena from $36.00 to $35.00 and set a “sector perform” rating for the company in a report on Friday, February 16th. Finally, Oppenheimer reduced their price target on shares of Prothena from $98.00 to $80.00 and set an “outperform” rating for the company in a report on Tuesday, February 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $68.14.

Prothena Stock Performance

Shares of PRTA stock opened at $20.87 on Friday. Prothena Co. plc has a 52-week low of $19.65 and a 52-week high of $79.65. The firm has a fifty day moving average of $25.37 and a 200-day moving average of $32.14.

Prothena (NASDAQ:PRTA) last announced its earnings results on Thursday, February 15th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.03). The firm had revenue of $0.32 million for the quarter, compared to analyst estimates of $2.15 million. Prothena had a negative return on equity of 24.84% and a negative net margin of 160.91%. The company’s revenue for the quarter was down 99.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.12 EPS. Sell-side analysts expect that Prothena Co. plc will post -4.88 earnings per share for the current year.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.